BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stewart CA, Malinchoc M, Kim WR, Kamath PS. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transpl 2007;13:1366-71. [DOI: 10.1002/lt.21129] [Cited by in Crossref: 184] [Cited by in F6Publishing: 143] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 Seraj SM, Campbell EJ, Argyropoulos SK, Wegermann K, Chung RT, Richter JM. Hospital readmissions in decompensated cirrhotics: Factors pointing toward a prevention strategy. World J Gastroenterol 2017; 23(37): 6868-6876 [PMID: 29085229 DOI: 10.3748/wjg.v23.i37.6868] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 16] [Article Influence: 5.2] [Reference Citation Analysis]
2 Francoz C, Belghiti J, Castaing D, Chazouillères O, Duclos-vallée J, Duvoux C, Lerut J, Le Treut Y, Moreau R, Mandot A, Pageaux G, Samuel D, Thabut D, Valla D, Durand F. Model for end-stage liver disease exceptions in the context of the french model for end-stage liver disease score-based liver allocation system: Meld Exceptions in the French System. Liver Transpl 2011;17:1137-51. [DOI: 10.1002/lt.22363] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
3 Katsounas A, Canbay A. Intensive Care Therapy for Patients with Advanced Liver Diseases. Visc Med 2018;34:283-9. [PMID: 30345286 DOI: 10.1159/000492088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
4 Bajaj JS, Schubert CM, Heuman DM, Wade JB, Gibson DP, Topaz A, Saeian K, Hafeezullah M, Bell DE, Sterling RK, Stravitz RT, Luketic V, White MB, Sanyal AJ. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology. 2010;138:2332-2340. [PMID: 20178797 DOI: 10.1053/j.gastro.2010.02.015] [Cited by in Crossref: 197] [Cited by in F6Publishing: 161] [Article Influence: 16.4] [Reference Citation Analysis]
5 Chen L, Xiao T, Chen W, Long Q, Li R, Fang D, Wang R. Outcomes of transjugular intrahepatic portosystemic shunt through the left branch vs. the right branch of the portal vein in advanced cirrhosis: a randomized trial. Liver Int. 2009;29:1101-1109. [PMID: 19386025 DOI: 10.1111/j.1478-3231.2009.02016.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
6 Stewart CA, Enders FT, Schneider N, Felmlee-Devine D, Kamath PS, Smith GE. Development of a three-factor neuropsychological approach for detecting minimal hepatic encephalopathy. Liver Int 2010;30:841-9. [PMID: 20412441 DOI: 10.1111/j.1478-3231.2010.02246.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
7 Zheng MH, Shi KQ, Lin XF, Xiao DD, Chen LL, Liu WY, Fan YC, Chen YP. A model to predict 3-month mortality risk of acute-on-chronic hepatitis B liver failure using artificial neural network. J Viral Hepat 2013;20:248-55. [PMID: 23490369 DOI: 10.1111/j.1365-2893.2012.01647.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
8 Prakash RK, Kanna S, Mullen KD. Evolving Concepts: The Negative Effect of Minimal Hepatic Encephalopathy and Role for Prophylaxis in Patients With Cirrhosis. Clinical Therapeutics 2013;35:1458-73. [DOI: 10.1016/j.clinthera.2013.07.421] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
9 Jia JD. Lactulose in the treatment of hepatic encephalopathy: new evidence for an old modality. J Gastroenterol Hepatol 2012;27:1262-3. [PMID: 22823914 DOI: 10.1111/j.1440-1746.2012.07177.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
10 Bhanji RA, Moctezuma-Velazquez C, Duarte-Rojo A, Ebadi M, Ghosh S, Rose C, Montano-Loza AJ. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis. Hepatol Int. 2018;12:377-386. [PMID: 29881992 DOI: 10.1007/s12072-018-9875-9] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 16.5] [Reference Citation Analysis]
11 Mardini H, Smith FE, Record CO, Blamire AM. Magnetic resonance quantification of water and metabolites in the brain of cirrhotics following induced hyperammonaemia. J Hepatol. 2011;54:1154-1160. [PMID: 21145802 DOI: 10.1016/j.jhep.2010.09.030] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
12 Elwir S, Rahimi RS. Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options. J Clin Transl Hepatol. 2017;5:142-151. [PMID: 28660152 DOI: 10.14218/jcth.2016.00069] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
13 Feuerstadt P, Hong SJ, Brandt LJ. Chronic Rifaximin Use in Cirrhotic Patients Is Associated with Decreased Rate of C. difficile Infection. Dig Dis Sci 2020;65:632-8. [DOI: 10.1007/s10620-019-05804-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Legaz I, Bolarin JM, Campillo JA, Moya RM, Luna A, Osuna E, Minguela A, Sanchez-Bueno F, Alvarez MR, Muro M. Pretransplant ascites and encephalopathy and their influence on survival and liver graft rejection in alcoholic cirrhosis disease. Arch Med Sci 2021;17:682-93. [PMID: 34025838 DOI: 10.5114/aoms.2018.80651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Bittencourt PL, Terra C, Parise ER, Farias AQ, Arroyo V, Fernandez J, Pereira G, Maubouisson LM, Andrade GM, Costa FG, Codes L, Andrade AR, Mattos AA, Torres A, Couto F, Zyngier I. Intensive care management of patients with liver disease: proceedings of a single-topic conference sponsored by the Brazilian Society of Hepatology. Arq Gastroenterol 2015;52 Suppl 1:55-72. [PMID: 26959806 DOI: 10.1590/S0004-28032015000500004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
16 Lee PC, Chen YJ, Chou YC, Lee KC, Chen PH, Kao WY, Huang YH, Huo TI, Lin HC, Hou MC, Lee FY, Wu JC, Su CW. Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 2020;32:365-72. [PMID: 31688303 DOI: 10.1097/MEG.0000000000001511] [Reference Citation Analysis]
17 Zeng G, Penninkilampi R, Chaganti J, Montagnese S, Brew BJ, Danta M. Meta-analysis of magnetic resonance spectroscopy in the diagnosis of hepatic encephalopathy. Neurology 2020;94:e1147-56. [DOI: 10.1212/wnl.0000000000008899] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
18 Huo TI, Lee SD, Lin HC. Selecting an optimal prognostic system for liver cirrhosis: the model for end-stage liver disease and beyond. Liver Int. 2008;28:606-613. [PMID: 18433390 DOI: 10.1111/j.1478-3231.2008.01727.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
19 Berni E, Murphy D, Whitehouse J, Conway P, Di Maggio P, Currie CJ, Poole C. Evaluation of the cost-effectiveness of rifaximin-α for the management of patients with hepatic encephalopathy in the United Kingdom. Current Medical Research and Opinion 2018;34:2001-8. [DOI: 10.1080/03007995.2018.1499506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications. Clin Mol Hepatol 2020;26:83-127. [PMID: 31918536 DOI: 10.3350/cmh.2019.0010n] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
21 Colmenero J, Castro-Narro G, Navasa M. [The value of MELD in the allocation of priority for liver transplantation candidates]. Gastroenterol Hepatol 2010;33:330-6. [PMID: 19631411 DOI: 10.1016/j.gastrohep.2009.04.007] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
22 Montoliu C, Gonzalez-Escamilla G, Atienza M, Urios A, Gonzalez O, Wassel A, Aliaga R, Giner-Duran R, Serra MA, Rodrigo JM. Focal cortical damage parallels cognitive impairment in minimal hepatic encephalopathy. Neuroimage. 2012;61:1165-1175. [PMID: 22465844 DOI: 10.1016/j.neuroimage.2012.03.041] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
23 Vernia F, Di Ruscio M, Ciccone A, Viscido A, Frieri G, Stefanelli G, Latella G. Sleep disorders related to nutrition and digestive diseases: a neglected clinical condition. Int J Med Sci 2021;18:593-603. [PMID: 33437194 DOI: 10.7150/ijms.45512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
24 Cui Y, Guan S, Ding J, He Y, Li Q, Wang S, Sun H. Establishment and evaluation of a model for predicting 3-month mortality in Chinese patients with hepatic encephalopathy. Metab Brain Dis 2019;34:213-21. [DOI: 10.1007/s11011-018-0333-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;CD003044. [PMID: 27153247 DOI: 10.1002/14651858.cd003044.pub4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
26 Formentin C, Zarantonello L, Mangini C, Frigo AC, Montagnese S, Merkel C. Clinical, neuropsychological and neurophysiological indices and predictors of hepatic encephalopathy (HE). Liver Int 2021;41:1070-82. [PMID: 33411388 DOI: 10.1111/liv.14785] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Chen XJ, Ma LQ. Role of farnesoid X receptor in nonalcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2015; 23(8): 1258-1265 [DOI: 10.11569/wcjd.v23.i8.1258] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
28 Stokes CS, Goh ET, Vilstrup H, Morgan MY, Gluud LL; Cochrane Hepato-Biliary Group. L-ornithine L-aspartate for people with cirrhosis and hepatic encephalopathy. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012410] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
29 Huang H, Lee F, Huo T. Major adverse events, pretransplant assessment and outcome prediction. Journal of Gastroenterology and Hepatology 2009;24:1716-24. [DOI: 10.1111/j.1440-1746.2009.06025.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
30 Zacharias HD, Zacharias AP, Gluud LL, Morgan MY. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis. Cochrane Database Syst Rev 2019;6:CD012334. [PMID: 31204790 DOI: 10.1002/14651858.CD012334.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
31 Campos-Varela I, Castells L. [Prognostic scores of cirrhosis]. Gastroenterol Hepatol 2008;31:439-46. [PMID: 18783690 DOI: 10.1157/13125591] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Stadlbauer V, Wright GAK, Jalan R. Role of artificial liver support in hepatic encephalopathy. Metab Brain Dis 2009;24:15-26. [DOI: 10.1007/s11011-008-9117-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
33 Goh ET, Andersen ML, Morgan MY, Gluud LL. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. Cochrane Database Syst Rev 2017;7:CD002798. [PMID: 28745801 DOI: 10.1002/14651858.CD002798.pub3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
34 Rivkin A, Gim S. Rifaximin: new therapeutic indication and future directions. Clin Ther. 2011;33:812-827. [PMID: 21741091 DOI: 10.1016/j.clinthera.2011.06.007] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
35 Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther. 2010;31:537-547. [PMID: 20002027 DOI: 10.1111/j.1365-2036.2009.04211.x] [Cited by in Crossref: 163] [Cited by in F6Publishing: 127] [Article Influence: 12.5] [Reference Citation Analysis]
36 Yu H, Chen Y, Jiang P. Prognostic value of hepatic encephalopathy for survival of patients with liver failure: A systematic review and meta-analysis. Ann Hepatol 2019;18:607-12. [PMID: 31085039 DOI: 10.1016/j.aohep.2019.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Hong G, Lee KW, Suh S, Yoo T, Kim H, Park MS, Choi Y, Yi NJ, Suh KS. The model for end-stage liver disease score-based system predicts short term mortality better than the current Child-Turcotte-Pugh score-based allocation system during waiting for deceased liver transplantation. J Korean Med Sci. 2013;28:1207-1212. [PMID: 23960449 DOI: 10.3346/jkms.2013.28.8.1207] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
38 Gallegos-Orozco JF, Vargas HE. Liver transplantation: from Child to MELD. Med Clin North Am. 2009;93:931-950, ix. [PMID: 19577123 DOI: 10.1016/j.mcna.2009.03.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
39 Li Y, He X, Pang H. A model to predict early hepatic encephalopathy in patients undergoing transjugular intrahepatic portosystemic shunt. Turk J Gastroenterol. 2019;30:702-707. [PMID: 31418414 DOI: 10.5152/tjg.2019.18485] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
40 Chautant F, Guillaume M, Robic MA, Cadranel JF, Peron JM, Lison H, Cool C, Bureau C, Duhalde V. Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy. World J Hepatol 2020; 12(1): 10-20 [PMID: 31984117 DOI: 10.4254/wjh.v12.i1.10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Goh ET, Andersen ML, Morgan MY, Gluud LL. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. Cochrane Database Syst Rev 2017;8:CD002798. [PMID: 28796283 DOI: 10.1002/14651858.CD002798.pub4] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
42 Kuang Y, Wu X, Lai H, Wang Z, Lei Q, Zhong W, Yang Y, Deng C, Zhou Z. Abnormal corpus callosum induced by overt hepatic encephalopathy impairs interhemispheric functional coordination in cirrhosis patients. Ann Transl Med 2021;9:1579. [PMID: 34790785 DOI: 10.21037/atm-21-5109] [Reference Citation Analysis]
43 Shehata HH, Elfert AA, Abdin AA, Soliman SM, Elkhouly RA, Hawash NI, Soliman HH. Randomized controlled trial of polyethylene glycol versus lactulose for the treatment of overt hepatic encephalopathy. Eur J Gastroenterol Hepatol 2018;30:1476-81. [PMID: 30234645 DOI: 10.1097/MEG.0000000000001267] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 4.7] [Reference Citation Analysis]
44 Kerbert AJC, Reverter E, Verbruggen L, Tieleman M, Navasa M, Mertens BJA, Rodríguez-Tajes S, de Vree M, Metselaar HJ, Chiang FWT, Verspaget HW, van Hoek B, Bosch J, Coenraad MJ. Impact of hepatic encephalopathy on liver transplant waiting list mortality in regions with different transplantation rates. Clin Transplant 2018;32:e13412. [PMID: 30230613 DOI: 10.1111/ctr.13412] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
45 Shawcross DL, Dunk AA, Jalan R, Kircheis G, de Knegt RJ, Laleman W, Ramage JK, Wedemeyer H, Morgan IE; New Insights Steering Committee. How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. Eur J Gastroenterol Hepatol. 2016;28:146-152. [PMID: 26600154 DOI: 10.1097/meg.0000000000000529] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
46 Vaz K, Little R, Majeed A, Kemp W, Roberts SK. Determinants of Short- and Long-Term Outcomes of an Australian Cohort of Patients Admitted with Alcoholic Hepatitis. Dig Dis Sci 2021. [PMID: 34231100 DOI: 10.1007/s10620-021-07140-w] [Reference Citation Analysis]
47 Zou TX, She L, Zhan C, Gao YQ, Chen HJ. Altered Topological Properties of Gray Matter Structural Covariance Networks in Minimal Hepatic Encephalopathy. Front Neuroanat 2018;12:101. [PMID: 30555305 DOI: 10.3389/fnana.2018.00101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
48 Romeiro FG, Augusti L. Nutritional assessment in cirrhotic patients with hepatic encephalopathy. World J Hepatol 2015; 7(30): 2940-2954 [PMID: 26730273 DOI: 10.4254/wjh.v7.i30.2940] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
49 Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol. 2012;107:1043-1050. [PMID: 22710579 DOI: 10.1038/ajg.2012.113] [Cited by in Crossref: 138] [Cited by in F6Publishing: 114] [Article Influence: 13.8] [Reference Citation Analysis]
50 Kalra A, Norvell JP. Cause for Confusion: Noncirrhotic Hyperammonemic Encephalopathy. Clin Liver Dis (Hoboken) 2020;15:223-7. [PMID: 32617154 DOI: 10.1002/cld.929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
51 Fallahzadeh MA, Rahimi RS. Hepatic Encephalopathy and Nutrition Influences: A Narrative Review. Nutr Clin Pract 2020;35:36-48. [PMID: 31872484 DOI: 10.1002/ncp.10458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
52 Ringe H, Varnholt V, Zimmering M, Luck W, Gratopp A, König K, Reich S, Sauer IM, Gaedicke G, Querfeld U. Continuous veno-venous single-pass albumin hemodiafiltration in children with acute liver failure. Pediatr Crit Care Med 2011;12:257-64. [PMID: 20921923 DOI: 10.1097/PCC.0b013e3181f35fa2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
53 Li X, Wu J, Mao W. Evaluation of the neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and red cell distribution width for the prediction of prognosis of patients with hepatitis B virus-related decompensated cirrhosis. J Clin Lab Anal 2020;34:e23478. [PMID: 32666632 DOI: 10.1002/jcla.23478] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
54 Lucidi C, Ginanni Corradini S, Abraldes JG, Merli M, Tandon P, Ferri F, Parlati L, Lattanzi B, Poli E, Di Gregorio V, Farcomeni A, Riggio O. Hepatic encephalopathy expands the predictivity of model for end-stage liver disease in liver transplant setting: Evidence by means of 2 independent cohorts. Liver Transpl 2016;22:1333-42. [DOI: 10.1002/lt.24517] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
55 O'Hara ME, Fernández Del Río R, Holt A, Pemberton P, Shah T, Whitehouse T, Mayhew CA. Limonene in exhaled breath is elevated in hepatic encephalopathy. J Breath Res 2016;10:046010. [PMID: 27869108 DOI: 10.1088/1752-7155/10/4/046010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
56 Bohra A, Worland T, Hui S, Terbah R, Farrell A, Robertson M. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care. World J Gastroenterol 2020; 26(18): 2221-2231 [PMID: 32476788 DOI: 10.3748/wjg.v26.i18.2221] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
57 Elsaid MI, Rustgi VK. Epidemiology of Hepatic Encephalopathy. Clinics in Liver Disease 2020;24:157-74. [DOI: 10.1016/j.cld.2020.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
58 Maan R, Darwish Murad S, van der Meer AJ. Letter to the Editor: Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: A Meta-analysis of Individual Patient Data. Gastroenterology 2021;161:371-2. [PMID: 33581122 DOI: 10.1053/j.gastro.2021.02.017] [Reference Citation Analysis]
59 Munoz SJ. Hepatic encephalopathy. Med Clin North Am. 2008;92:795-812, viii. [PMID: 18570943 DOI: 10.1016/j.mcna.2008.03.009] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
60 Zhao X, Wong P. Managing Sleep Disturbances in Cirrhosis. Scientifica (Cairo) 2016;2016:6576812. [PMID: 27242950 DOI: 10.1155/2016/6576812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
61 Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;4:CD003044. [PMID: 27089005 DOI: 10.1002/14651858.cd003044.pub3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
62 Khungar V, Poordad F. Hepatic encephalopathy. Clin Liver Dis. 2012;16:301-320. [PMID: 22541700 DOI: 10.1016/j.cld.2011.12.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
63 Bajaj JS, Schubert CM, Heuman DM, Wade JB, Gibson DP, Topaz A, Saeian K, Hafeezullah M, Bell DE, Sterling RK. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology. 2010;138:2332-2340. [PMID: 20178797 DOI: 10.1038/ajg.2011.490] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Bajaj JS, Barrett AC, Bortey E, Paterson C, Forbes WP. Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis. Aliment Pharmacol Ther. 2015;41:39-45. [PMID: 25339518 DOI: 10.1111/apt.12993] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
65 Jeong JH, Park IS, Kim DH, Kim SC, Kang C, Lee SH, Kim TY, Lee SB. CLIF-SOFA score and SIRS are independent prognostic factors in patients with hepatic encephalopathy due to alcoholic liver cirrhosis. Medicine (Baltimore). 2016;95:e3935. [PMID: 27367990 DOI: 10.1097/md.0000000000003935] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
66 Bajaj JS, Kamath PS. The brain gets its say: Hepatic encephalopathy and its evolving role in transplant priority. Liver Transpl 2016;22:1319-20. [PMID: 27509240 DOI: 10.1002/lt.24521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
67 Romeiro FG, Ietsugu MDV, Franzoni LC, Augusti L, Alvarez M, Santos LAA, Lima TB, Koga KH, Moriguchi SM, Caramori CA, Silva GF, Betting LEGG. Which of the branched-chain amino acids increases cerebral blood flow in hepatic encephalopathy? A double-blind randomized trial. Neuroimage Clin 2018;19:302-10. [PMID: 30013913 DOI: 10.1016/j.nicl.2018.03.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Chen HJ, Wang Y, Zhu XQ, Cui Y, Chen YC, Teng GJ. White matter abnormalities correlate with neurocognitive performance in patients with HBV-related cirrhosis. J Neurol Sci. 2012;321:65-72. [PMID: 22877508 DOI: 10.1016/j.jns.2012.07.056] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
69 Goldbecker A, Weissenborn K, Hamidi Shahrezaei G, Afshar K, Rümke S, Barg-Hock H, Strassburg CP, Hecker H, Tryc AB. Comparison of the most favoured methods for the diagnosis of hepatic encephalopathy in liver transplantation candidates. Gut. 2013;62:1497-1504. [PMID: 23297006 DOI: 10.1136/gutjnl-2012-303262] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 6.7] [Reference Citation Analysis]
70 Bajaj JS, Thacker LR, Heuman DM, Sterling RK, Stravitz RT, Sanyal AJ, Luketic V, Fuchs M, Gilles HC, Wade JB. Cognitive performance as a predictor of hepatic encephalopathy in pretransplant patients with cirrhosis receiving psychoactive medications: a prospective study. Liver Transpl. 2012;18:1179-1187. [PMID: 22674517 DOI: 10.1002/lt.23484] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
71 Murai Y, Ohfuji S, Fukushima W, Tamakoshi A, Yamaguchi S, Hashizume M, Moriyasu F, Hirota Y. Prognostic factors in patients with idiopathic portal hypertension: Two Japanese nationwide epidemiological surveys in 1999 and 2005: Prognostic factors of IPH patients. Hepatology Research 2012;42:1211-20. [DOI: 10.1111/j.1872-034x.2012.01033.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
72 Mikkelsen MR, Hendriksen C, Schiødt FV, Rydahl-hansen S. Coping and rehabilitation in alcoholic liver disease patients after hepatic encephalopathy - in interaction with professionals and relatives. J Clin Nurs 2015;24:3627-37. [DOI: 10.1111/jocn.13006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
73 Durand F, Roux O, Weiss E, Francoz C. Acute-on-chronic liver failure: Where do we stand? Liver Int 2021;41 Suppl 1:128-36. [PMID: 34155793 DOI: 10.1111/liv.14855] [Reference Citation Analysis]
74 Holte K, Krag A, Gluud LL. Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy. Hepatol Res 2012;42:1008-15. [PMID: 22548675 DOI: 10.1111/j.1872-034X.2012.01015.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 12] [Article Influence: 3.9] [Reference Citation Analysis]
75 Maggi DC, Borgonovo A, Bansho ET, Soares-silva PE, Silva TE, Colombo BS, Wildner LM, Bazzo ML, Dantas-correa EB, Narciso-schiavon JL, Schiavon LL. Serial assessment of hepatic encephalopathy in patients hospitalised for acute decompensation of cirrhosis. Annals of Hepatology 2019;18:331-7. [DOI: 10.1016/j.aohep.2018.11.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
76 Gadiparthi C, Cholankeril G, Yoo ER, Hu M, Wong RJ, Ahmed A. Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy. Dig Dis Sci 2018;63:1647-53. [DOI: 10.1007/s10620-018-5032-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
77 Zamora Nava LE, Delgadillo AT. Minimal hepatic encephalopathy. Annals of Hepatology 2011;10:S50-4. [DOI: 10.1016/s1665-2681(19)31607-2] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
78 Nath A, Haktanirlar G, Varga Á, Molnár MA, Albert K, Galambos I, Koris A, Vatai G. Biological Activities of Lactose-Derived Prebiotics and Symbiotic with Probiotics on Gastrointestinal System. Medicina (Kaunas) 2018;54:E18. [PMID: 30344249 DOI: 10.3390/medicina54020018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
79 Mantry PS, Munsaf S. Rifaximin for the treatment of hepatic encephalopathy. Transplant Proc. 2010;42:4543-4547. [PMID: 21168733 DOI: 10.1016/j.transproceed.2010.09.173] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
80 Mikkelsen MR, Hendriksen C, Schiødt FV, Rydahl-hansen S. Alcoholic liver disease patients’ perspective of a coping and physical activity-oriented rehabilitation intervention after hepatic encephalopathy. J Clin Nurs 2016;25:2457-67. [DOI: 10.1111/jocn.13265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
81 Amodio P. The liver, the brain and nitrogen metabolism. Metab Brain Dis. 2009;24:1-4. [PMID: 19107584 DOI: 10.1007/s11011-008-9120-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
82 Higuera-de-la-Tijera F, Servín-Caamaño AI, Salas-Gordillo F, Pérez-Hernández JL, Abdo-Francis JM, Camacho-Aguilera J, Alla SN, Jiménez-Ponce F. Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding. Can J Gastroenterol Hepatol 2018;2018:3015891. [PMID: 30079329 DOI: 10.1155/2018/3015891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
83 Ditisheim S, Giostra E, Burkhard PR, Goossens N, Mentha G, Hadengue A, Spahr L. A capillary blood ammonia bedside test following glutamine load to improve the diagnosis of hepatic encephalopathy in cirrhosis. BMC Gastroenterol 2011;11:134. [PMID: 22151412 DOI: 10.1186/1471-230X-11-134] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Gluud LL, Jeyaraj R, Morgan MY. Outcomes in Clinical Trials Evaluating Interventions for the Prevention and Treatment of Hepatic Encephalopathy. J Clin Exp Hepatol 2019;9:354-61. [PMID: 31360028 DOI: 10.1016/j.jceh.2019.02.004] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Thornton JG, Mullen KD. The role of hepatic encephalopathy in the era of MELD. Liver Transpl 2007;13:1364-5. [DOI: 10.1002/lt.21229] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
86 Cunniffe N, Munby H, Chan S, Saatci D, Edison E, Carpenter RHS, Massey D. Using saccades to diagnose covert hepatic encephalopathy. Metab Brain Dis 2015;30:821-8. [DOI: 10.1007/s11011-014-9647-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
87 Jackson CD, Gram M, Halliday E, Olesen SS, Sandberg TH, Drewes AM, Morgan MY. New spectral thresholds improve the utility of the electroencephalogram for the diagnosis of hepatic encephalopathy. Clin Neurophysiol 2016;127:2933-41. [PMID: 27236607 DOI: 10.1016/j.clinph.2016.03.027] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
88 Thomsen KL, Macnaughtan J, Tritto G, Mookerjee RP, Jalan R. Clinical and Pathophysiological Characteristics of Cirrhotic Patients with Grade 1 and Minimal Hepatic Encephalopathy. PLoS One. 2016;11:e0146076. [PMID: 26745876 DOI: 10.1371/journal.pone.0146076] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
89 Bannister CA, Orr JG, Reynolds AV, Hudson M, Conway P, Radwan A, Morgan CL, Currie CJ. Natural History of Patients Taking Rifaximin-α for Recurrent Hepatic Encephalopathy and Risk of Future Overt Episodes and Mortality: A Post-hoc Analysis of Clinical Trials Data. Clin Ther 2016;38:1081-1089.e4. [PMID: 27136714 DOI: 10.1016/j.clinthera.2016.03.033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
90 Peng Y, Qi X, Guo X. Child-Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Observational Studies. Medicine (Baltimore). 2016;95:e2877. [PMID: 26937922 DOI: 10.1097/md.0000000000002877] [Cited by in Crossref: 168] [Cited by in F6Publishing: 88] [Article Influence: 28.0] [Reference Citation Analysis]
91 Suzuki K, Endo R, Takikawa Y, Moriyasu F, Aoyagi Y, Moriwaki H, Terai S, Sakaida I, Sakai Y, Nishiguchi S, Ishikawa T, Takagi H, Naganuma A, Genda T, Ichida T, Takaguchi K, Miyazawa K, Okita K. Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial. Hepatol Res. 2018;48:411-423. [PMID: 29235218 DOI: 10.1111/hepr.13045] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
92 Luo M, Li L, Lu CZ, Cao WK. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol. 2011;23:1250-1257. [PMID: 21971378 DOI: 10.1097/meg.0b013e32834d1938] [Cited by in Crossref: 43] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
93 Neff GW, Jones M, Broda T, Jonas M, Ravi R, Novick D, Kaiser TE, Kemmer N. Durability of rifaximin response in hepatic encephalopathy. J Clin Gastroenterol. 2012;46:168-171. [PMID: 22011586 DOI: 10.1097/mcg.0b013e318231faae] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
94 Martín–llahí M, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, Solá E, Pereira G, Marinelli M, Pavesi M, Fernández J, Rodés J, Arroyo V, Ginès P. Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis. Gastroenterology 2011;140:488-496.e4. [DOI: 10.1053/j.gastro.2010.07.043] [Cited by in Crossref: 217] [Cited by in F6Publishing: 172] [Article Influence: 19.7] [Reference Citation Analysis]
95 Liu J, Wehrenberg-Klee EP, Bethea ED, Uppot RN, Yamada K, Ganguli S. Transjugular Intrahepatic Portosystemic Shunt Placement for Portal Hypertension: Meta-Analysis of Safety and Efficacy of 8 mm vs. 10 mm Stents. Gastroenterol Res Pract 2020;2020:9149065. [PMID: 33123192 DOI: 10.1155/2020/9149065] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
96 Dhiman RK, Thumburu KK, Verma N, Chopra M, Rathi S, Dutta U, Singal AK, Taneja S, Duseja A, Singh M. Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis.Clin Gastroenterol Hepatol. 2020;18:800-812.e25. [PMID: 31476436 DOI: 10.1016/j.cgh.2019.08.047] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
97 Routhu M, Safka V, Routhu SK, Fejfar T, Jirkovsky V, Krajina A, Cermakova E, Hosak L, Hulek P. Observational cohort study of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS). Ann Hepatol. 2017;16:140-148. [PMID: 28051803 DOI: 10.5604/16652681.1226932] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
98 Hassanein T. Current state of knowledge of hepatic encephalopathy (part IV): Management of Hepatic Encephalopathy by liver support systems. Metab Brain Dis 2017;32:303-6. [PMID: 28013444 DOI: 10.1007/s11011-016-9911-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Huo TI, Lin HC, Huo SC, Lee PC, Wu JC, Lee FY, Hou MC, Lee SD. Comparison of four model for end-stage liver disease-based prognostic systems for cirrhosis. Liver Transpl. 2008;14:837-844. [PMID: 18508377 DOI: 10.1002/lt.21439] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
100 Zuo L, Lv Y, Wang Q, Yin Z, Wang Z, He C, Guo W, Niu J, Bai W, Li K, Yu T, Yuan X, Chen H, Liu H, Xia D, Wang E, Luo B, Li X, Yuan J, Han N, Nie Y, Fan D, Han G. Early-Recurrent Overt Hepatic Encephalopathy Is Associated with Reduced Survival in Cirrhotic Patients after Transjugular Intrahepatic Portosystemic Shunt Creation. J Vasc Interv Radiol. 2019;30:148-153.e2. [PMID: 30638778 DOI: 10.1016/j.jvir.2018.08.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
101 Cai M, Han Z, He X, Zhang J. Usefulness of International Normalized Ratio to Albumin Ratio for Evaluation of Mortality in Hepatitis B Virus-Associated Decompensated Cirrhosis. Biomed Res Int 2021;2021:6664574. [PMID: 34055994 DOI: 10.1155/2021/6664574] [Reference Citation Analysis]
102 Kuan YC, Huang KW, Lin CL, Luo JC, Kao CH. Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis. J Clin Med 2019;8:E1108. [PMID: 31349746 DOI: 10.3390/jcm8081108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
103 Patidar KR, Bajaj JS. Covert and Overt Hepatic Encephalopathy: Diagnosis and Management. Clin Gastroenterol Hepatol 2015;13:2048-61. [PMID: 26164219 DOI: 10.1016/j.cgh.2015.06.039] [Cited by in Crossref: 87] [Cited by in F6Publishing: 65] [Article Influence: 12.4] [Reference Citation Analysis]
104 Chacko KR, Sigal SH. Update on management of patients with overt hepatic encephalopathy. Hosp Pract (1995) 2013;41:48-59. [PMID: 23948621 DOI: 10.3810/hp.2013.08.1068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
105 Agrawal S, Umapathy S, Dhiman RK. Minimal hepatic encephalopathy impairs quality of life. J Clin Exp Hepatol. 2015;5:S42-S48. [PMID: 26041957 DOI: 10.1016/j.jceh.2014.11.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
106 Lladó L, Bustamante J. IV Reunión de Consenso de la Sociedad Española de Trasplante Hepático 2012. Excepciones al Model for End-stage Liver Disease en la priorización para trasplante hepático. Gastroenterología y Hepatología 2014;37:83-91. [DOI: 10.1016/j.gastrohep.2013.06.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
107 Mullen K, Prakash R. Rifaximin for the treatment of hepatic encephalopathy. Expert Rev Gastroenterol Hepatol 2010;4:665-77. [PMID: 21108586 DOI: 10.1586/egh.10.78] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
108 Chen HJ, Chen R, Yang M, Teng GJ, Herskovits EH. Identification of minimal hepatic encephalopathy in patients with cirrhosis based on white matter imaging and Bayesian data mining. AJNR Am J Neuroradiol 2015;36:481-7. [PMID: 25500314 DOI: 10.3174/ajnr.A4146] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
109 Zhang J, Liu X, Ye B, Chen H. Ammonia predicts poor outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure. J Clin Lab Anal 2020;34:e23553. [PMID: 32914901 DOI: 10.1002/jcla.23553] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
110 Acharya C, Bajaj JS. Hepatic Encephalopathy and Liver Transplantation: The Past, Present, and Future Toward Equitable Access. Liver Transpl 2021. [PMID: 34018659 DOI: 10.1002/lt.26099] [Reference Citation Analysis]
111 Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010;7:515-25. [DOI: 10.1038/nrgastro.2010.116] [Cited by in Crossref: 174] [Cited by in F6Publishing: 152] [Article Influence: 14.5] [Reference Citation Analysis]
112 Montagnese S, De Rui M, Schiff S, Ceranto E, Valenti P, Angeli P, Cillo U, Zanus G, Gatta A, Amodio P. Prognostic benefit of the addition of a quantitative index of hepatic encephalopathy to the MELD score: the MELD-EEG. Liver Int. 2015;35:58-64. [PMID: 24517387 DOI: 10.1111/liv.12490] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
113 Ampuero J, Simón M, Montoliú C, Jover R, Serra MÁ, Córdoba J, Romero-Gómez M. Minimal hepatic encephalopathy and critical flicker frequency are associated with survival of patients with cirrhosis. Gastroenterology 2015;149:1483-9. [PMID: 26299413 DOI: 10.1053/j.gastro.2015.07.067] [Cited by in Crossref: 74] [Cited by in F6Publishing: 60] [Article Influence: 10.6] [Reference Citation Analysis]
114 Schilsky ML, Moini M. Advances in liver transplantation allocation systems. World J Gastroenterol 2016; 22(10): 2922-2930 [PMID: 26973389 DOI: 10.3748/wjg.v22.i10.2922] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
115 Poh Z, Chang PE. A current review of the diagnostic and treatment strategies of hepatic encephalopathy. Int J Hepatol. 2012;2012:480309. [PMID: 23133760 DOI: 10.1155/2012/480309] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
116 Allegretti AS, Frenk NE, Li DK, Seethapathy H, Vela Parada XF, Long J, Endres P, Pratt DS, Chung RT, Ganguli S, Irani Z, Yamada K. Evaluation of model performance to predict survival after transjugular intrahepatic portosystemic shunt placement. PLoS One 2019;14:e0217442. [PMID: 31120995 DOI: 10.1371/journal.pone.0217442] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
117 Mendieta Zerón H, Rodríguez MR, Montes S, Castañeda CR. Blood manganese levels in patients with hepatic encephalopathy. Journal of Trace Elements in Medicine and Biology 2011;25:225-9. [DOI: 10.1016/j.jtemb.2011.07.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
118 Saab S, Suraweera D, Au J, Saab EG, Alper TS, Tong MJ. Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials. Liver Int. 2016;36:986-993. [PMID: 26561214 DOI: 10.1111/liv.13005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
119 Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology. 2009;50:2014-2021. [PMID: 19787808 DOI: 10.1002/hep.23216] [Cited by in Crossref: 223] [Cited by in F6Publishing: 198] [Article Influence: 17.2] [Reference Citation Analysis]
120 Wu D, Wu SM, Lu J, Zhou YQ, Xu L, Guo CY. Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis. Gastroenterol Res Pract. 2013;2013:236963. [PMID: 23653636 DOI: 10.1155/2013/236963] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
121 Grover VP, Crossey MM, Fitzpatrick JA, Saxby BK, Shaw R, Waldman AD, Morgan MY, Taylor-Robinson SD. Quantitative magnetic resonance imaging in patients with cirrhosis: a cross-sectional study. Metab Brain Dis 2016;31:1315-25. [PMID: 26251205 DOI: 10.1007/s11011-015-9716-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
122 Khungar V, Poordad F. Management of overt hepatic encephalopathy. Clin Liver Dis. 2012;16:73-89. [PMID: 22321466 DOI: 10.1016/j.cld.2012.03.009] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
123 Elwir S, Hal H, Veith J, Schreibman I, Kadry Z, Riley T. Radiographical findings in patients with liver cirrhosis and hepatic encephalopathy. Gastroenterol Rep (Oxf) 2016;4:221-5. [PMID: 26463277 DOI: 10.1093/gastro/gov049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
124 Le Corvec M, Jezequel C, Monbet V, Fatih N, Charpentier F, Tariel H, Boussard-Plédel C, Bureau B, Loréal O, Sire O, Bardou-Jacquet E. Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis. PLoS One 2017;12:e0185997. [PMID: 29020046 DOI: 10.1371/journal.pone.0185997] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
125 Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2018;5:CD012410. [PMID: 29762873 DOI: 10.1002/14651858.cd012410.pub2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
126 Stewart CA, Smith GE. Minimal hepatic encephalopathy. Nat Clin Pract Gastroenterol Hepatol. 2007;4:677-685. [PMID: 18043677 DOI: 10.1038/ncpgasthep0999] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 4.1] [Reference Citation Analysis]
127 Arasaradnam RP, McFarlane M, Ling K, Wurie S, O'Connell N, Nwokolo CU, Bardhan KD, Skinner J, Savage RS, Covington JA. Breathomics--exhaled volatile organic compound analysis to detect hepatic encephalopathy: A pilot study. J Breath Res. 2016;10:016012. [PMID: 26866470 DOI: 10.1088/1752-7155/10/1/016012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
128 Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, Uribe M, Vilstrup H, Morgan MY. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013;58:325-336. [PMID: 23471642 DOI: 10.1002/hep.26370] [Cited by in Crossref: 219] [Cited by in F6Publishing: 174] [Article Influence: 24.3] [Reference Citation Analysis]
129 Kaplan DE, Dai F, Skanderson M, Aytaman A, Baytarian M, D'Addeo K, Fox R, Hunt K, Knott A, Mehta R, Pedrosa M, Pocha C, Valderrama A, Taddei T; VOCAL Study Group. Recalibrating the Child-Turcotte-Pugh Score to Improve Prediction of Transplant-Free Survival in Patients with Cirrhosis. Dig Dis Sci 2016;61:3309-20. [PMID: 27405990 DOI: 10.1007/s10620-016-4239-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
130 Teperman LW, Peyregne VP. Considerations on the impact of hepatic encephalopathy treatments in the pretransplant setting. Transplantation 2010;89:771-8. [PMID: 20110852 DOI: 10.1097/TP.0b013e3181d2fe66] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Kachaamy T, Bajaj JS, Heuman DM. Muscle and Mortality in Cirrhosis. Clinical Gastroenterology and Hepatology 2012;10:100-2. [DOI: 10.1016/j.cgh.2011.11.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
132 Dhiman RK, Rana B, Agrawal S, Garg A, Chopra M, Thumburu KK, Khattri A, Malhotra S, Duseja A, Chawla YK. Probiotic VSL#3 Reduces Liver Disease Severity and Hospitalization in Patients With Cirrhosis: A Randomized, Controlled Trial. Gastroenterology 2014;147:1327-1337.e3. [DOI: 10.1053/j.gastro.2014.08.031] [Cited by in Crossref: 180] [Cited by in F6Publishing: 160] [Article Influence: 22.5] [Reference Citation Analysis]
133 Bajaj JS, O'Leary JG, Tandon P, Wong F, Garcia-Tsao G, Kamath PS, Maliakkal B, Biggins SW, Thuluvath PJ, Fallon MB, Subramanian RM, Vargas HE, Lai J, Thacker LR, Reddy KR. Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ Failures. Clin Gastroenterol Hepatol 2017; 15: 565-574. e4. [PMID: 27720916 DOI: 10.1016/j.cgh.2016.09.157] [Cited by in Crossref: 60] [Cited by in F6Publishing: 44] [Article Influence: 10.0] [Reference Citation Analysis]
134 Khodadoostan M, Sadeghian S, Safaei A, Kabiri M, Shavakhi S, Shavakhi AR, Shavakhi A. Detection of Minimal Hepatic Encephalopathy in Iranian Patients with Cirrhosis. Middle East J Dig Dis 2018;10:230-5. [PMID: 31049170 DOI: 10.15171/mejdd.2018.115] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
135 Sturm L, Bettinger D, Giesler M, Boettler T, Schmidt A, Buettner N, Thimme R, Schultheiss M. Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS). United European Gastroenterol J 2018;6:1380-90. [PMID: 30386611 DOI: 10.1177/2050640618795928] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
136 Leise MD, Poterucha JJ, Kamath PS, Kim WR. Management of hepatic encephalopathy in the hospital. Mayo Clin Proc 2014;89:241-53. [PMID: 24411831 DOI: 10.1016/j.mayocp.2013.11.009] [Cited by in Crossref: 64] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
137 Augusti L, Franzoni LC, Santos LA, Lima TB, Ietsugu MV, Koga KH, Moriguchi SM, Betting LE, Caramori CA, Silva GF, Romeiro FG. Lower values of handgrip strength and adductor pollicis muscle thickness are associated with hepatic encephalopathy manifestations in cirrhotic patients. Metab Brain Dis 2016;31:909-15. [PMID: 27131802 DOI: 10.1007/s11011-016-9828-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
138 Gao S, Huan S, Han L, Li F, Ji X, Li X, Fan Y, Wang K. Overexpression of serum sST2 is associated with poor prognosis in acute-on-chronic hepatitis B liver failure. Clinics and Research in Hepatology and Gastroenterology 2015;39:315-23. [DOI: 10.1016/j.clinre.2014.10.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
139 Platts-Mills TF, Richmond NL, LeFebvre EM, Mangipudi SA, Hollowell AG, Travers D, Biese K, Hanson LC, Volandes AE. Availability of Advance Care Planning Documentation for Older Emergency Department Patients: A Cross-Sectional Study. J Palliat Med 2017;20:74-8. [PMID: 27622294 DOI: 10.1089/jpm.2016.0243] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
140 Zheng MH, Shi KQ, Fan YC, Li H, Ye C, Chen QQ, Chen YP. A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. Clin Gastroenterol Hepatol. 2011;9:351-356.e3. [PMID: 21195790 DOI: 10.1016/j.cgh.2010.12.027] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
141 Kato K, Okumura K, Suzuki S, Matsuyama A, Hirabayashi H, Hattori R. Hyperammonemic encephalopathy associated with post-radiotherapy vesicointestinal fistula following cervical cancer. J Obstet Gynaecol Res 2021;47:2790-3. [PMID: 34038978 DOI: 10.1111/jog.14865] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, Kim YS, Lee JW, Kim DJ, Cho SW, Hwang SG, Sohn JH, Kim MY, Kim YB, Kim JG, Cho YK, Choi MS, Kim HJ, Lee HW, Kim SU, Kim JK, Choi JY, Jun DW, Tak WY, Lee BS, Jang BK, Chung WJ, Kim HS, Jang JY, Jeong SW, Kim SG, Kwon OS, Jung YK, Choe WH, Lee JS, Kim IH, Shim JJ, Cheon GJ, Bae SH, Seo YS, Choi DH, Jang SJ; Korean Association for the Study of the Liver. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012;18:1-21. [PMID: 22511898 DOI: 10.3350/kjhep.2012.18.1.1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 9.4] [Reference Citation Analysis]
143 Gao S, Ji XF, Li F, Sun FK, Zhao J, Fan YC, Wang K. Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 predicts prognosis of acute-on-chronic hepatitis B liver failure. J Viral Hepat 2015;22:112-9. [PMID: 24995843 DOI: 10.1111/jvh.12277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
144 Mullen KD, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, Frederick RT, Bortey E, Forbes WP. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2014; 12: 1390-7. e2. [PMID: 24365449 DOI: 10.1016/j.cgh.2013.12.021] [Cited by in Crossref: 116] [Cited by in F6Publishing: 94] [Article Influence: 12.9] [Reference Citation Analysis]
145 Yang HY, Chen DH, Gong HT, Zheng PY. Advances in diagnosis and treatment of minimal hepatic encephalopathy. Shijie Huaren Xiaohua Zazhi 2012; 20(22): 2058-2062 [DOI: 10.11569/wcjd.v20.i22.2058] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
146 Jesús Maldonado-garza H, Vázquez-elizondo G, Obed Gaytán-torres J, Ricardo Flores-rendón Á, Graciela Cárdenas-sandoval M, Javier Bosques-padilla F. Prevalence of minimal hepatic encephalopathy in cirrhotic patients. Annals of Hepatology 2011;10:S40-4. [DOI: 10.1016/s1665-2681(19)31605-9] [Cited by in Crossref: 19] [Article Influence: 1.7] [Reference Citation Analysis]
147 Gençdal G, Türker G, Yazıcı Gençdal I, Ekinci B, Acar Ş, Dinçkan A, Akyıldız M. Assessment of sleep pattern and quality before and after liver transplantation using different methods. Turk J Gastroenterol 2020;31:581-7. [PMID: 32915146 DOI: 10.5152/tjg.2020.18809] [Reference Citation Analysis]
148 Chung HS, Jung DH, Park CS. Intraoperative predictors of short-term mortality in living donor liver transplantation due to acute liver failure. Transplant Proc. 2013;45:236-240. [PMID: 23375307 DOI: 10.1016/j.transproceed.2012.06.077] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]